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We used the multilocus sequence typing (MLST) method to evaluate the genetic diversity of 46 Campylobacter
jejuni isolates from chickens and to determine the link between quinolone resistance and sequence type (ST).
There were a total of 16 ST genotypes, and the majority of them belonged to seven clonal complexes previously
identified by using isolates from human disease. The ST-353 complex was the most common complex, whereas
the ST-21, ST-42, ST-52, and ST-257 complexes were less well represented. The resistance phenotype varied for
each ST, and the Thr-86-Ile substitution in the GyrA protein was the predominant mechanism of resistance to
quinolone. Nine of the 14 isolates having the Thr-86-Ile substitution belonged to the ST-353 complex. MLST
showed that the emergence of quinolone resistance is not related to the diffusion of a unique clone and that
there is no link between ST genotype and quinolone resistance. Based on silent mutations, different variants
of the gyrA gene were shown to exist for the same ST. These data provide useful information for understanding
the epidemiology of C. jejuni in Senegal.
Campylobacter jejuni is the leading cause of bacterial food-
borne diarrheal disease throughout the world (2). In develop-
ing countries, the estimated incidence of Campylobacter in
diarrhea is between 40,000 and 60,000 per 100,000 for children
less than 5 years old and is 90 per 100,000 in the general
population (3, 5, 19). Organisms are carried in the intestinal
tracts of many animals, including birds, and epidemiological
evidence has suggested that this site is a potential reservoir for
human infections and an entry point into the food chain (12,
14, 17, 22). Most human infections with C. jejuni are self-
limiting and do not require antimicrobial therapy. However,
treatment with erythromycin or a fluoroquinolone is needed in
individuals with invasive or severe disease, in immunocompro-
mised patients, or in children less than 5 years old. But resis-
tance to fluoroquinolone is increasing throughout the world
(10). In Campylobacter, the predominant mechanism of fluo-
roquinolone resistance is the C-to-T transition at codon 86 in
the quinolone resistance-determining region (QRDR) of the
gyrA gene, which results in a threonine-to-isoleucine substitu-
tion in the functional protein (1, 24).
To study the epidemiology of Campylobacter infections, mul-
tiple typing methods have been developed in order to differ-
entiate isolates below the species level (25). The multilocus
sequence typing (MLST) method was developed by Dingle et
al. (8) to characterize C. jejuni strains and to identify clonal
lineages in this species (6, 7, 9, 16). This method uses genetic
variations at multiple chromosomal locations and allows gen-
eration of sequence data, which may be available via the In-
ternet for comparison with DNA sequences of other strains.
To date, there are little data on the epidemiology of Campy-
lobacter in Senegal; one study was a study of the incidence of
quinolone-resistant C. jejuni isolates in commercial chickens,
which was 40% (4).
The aims of the present study were (i) to evaluate the ge-
netic diversity of C. jejuni strains isolated from chickens in
Senegal and (ii) to determine the link between quinolone re-
sistance and sequence type (ST) genotypes.
MATERIALS AND METHODS
Campylobacter isolates. The C. jejuni isolates used originated from chicken
carcasses and were collected during 2000 to 2002 in the Dakar region (Senegal)
and suburbs (4). All of the bacterial isolates had been maintained as stock
cultures in glycerol broth at 80°C. A total of 46 isolates that were randomly
picked from 99 C. jejuni isolates were included in the study, and these strains
were obtained from 14 dispersed collection sites over a 3-year period. Prior to
DNA extraction, cultures were removed from storage and allowed to thaw at
room temperature. Isolates were cultured on Columbia agar plates containing
5% sheep blood and were incubated under microaerophilic conditions (5% O2,
10% CO2, 85% N2) at 42°C for 48 h.
MLST. Bacterial DNA was prepared by boiling as reported previously (1).
MLST was performed as described by Dingle et al. (8) by using sequences
obtained from seven housekeeping genes. PCR products were purified with a
QIAquick gel extraction kit (QIAGEN, Germany), and the DNA sequences of
both strands were determined with an ABI PRISM 310 DNA sequencer (Ap-
plied Biosystems). MLST alleles and sequence types were assigned to the isolates
by comparing data to the Campylobacter MLST database (http://campylobacter
.mlst.net). The isolates were organized into lineages with the program BURST
(based on related STs), which is part of the START (sequence type assignment
recombination tests) group of programs. Isolates were grouped together if they
shared five, six, or all seven MLST loci. eBURST was used to examine patterns
of evolutionary descent (11). Analysis of fixed differences, polymorphic sites, and
the ratio of nonsynonymous substitutions to synonymous substitutions was per-
formed with the DnaSP software package (version 4.00), available at http://www
.ub.edu/dnasp/ (20). The index of association (IA) was calculated using the
program START (15).
Antibiotic susceptibility. The antibiotic susceptibility of each isolate was de-
termined by the disk diffusion method. The MICs of ciprofloxacin and nalidixic
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acid were determined by the Etest method and were interpreted according to
CLSI (formerly NCCLS) guidelines (18). Isolates were inoculated onto Mueller-
Hinton blood agar, and Etest strips (AB Biodisk, Solna, Sweden) were applied to
each plate. C. jejuni subsp. jejuni ATCC 33560 ( NCTC 11351) was included as
a quality control strain. The plates were incubated at 42°C under microaerophilic
conditions (5% O2, 10% CO2, 85% N2) for 24 h. The breakpoint for ciprofloxa-
cin was considered to be an MIC of 4 g/ml.
Determination of mutations in the QRDR of gyrA. A 220-bp fragment covering
the QRDR of gyrA was amplified by PCR by using the primers and conditions
described previously, except that the annealing temperature was 50°C (24). After
purification (QIAquick gel extraction kit; QIAGEN, Germany), sequencing of
the amplified fragment was performed with the same primers using an ABI
PRISM 310 DNA sequencer (Applied Biosystems). DNA sequences were com-
pared to the previously published C. jejuni sequence (GenBank accession num-
ber L04566) using the CLUSTALW program available at http://bioweb.pasteur
.fr/seqanal/interfaces/clustalw.html.
RESULTS
Diversity of MLST alleles. The number of unique alleles at
each locus varied from five for the Asp locus to nine for the
Gln locus, and the percentage of variable sites in the data set
ranged from 0.6% for the uncA locus to 4.8% for the pgm locus
(Table 1). For all seven loci, the ratio of nonsynonymous sub-
stitutions to synonymous substitutions was much less than 1.
Diversity of STs and lineages. There were a total of 16 STs
among the 46 isolates examined. Several of these STs (ST1035,
ST1036, ST1037, ST1038, ST1039, ST1040, ST1041, ST1081,
ST1358, ST1359, and ST1370) had not been described previously
at the Campylobacter MLST database (http://campylobacter.mlst
.net). Using the program BURST, the 46 isolates were grouped
into four lineages (Table 2), and seven singleton sequence types
were unrelated to any other sequence types based on the fact that
the isolates in one group were identical at five, six, or all seven of
the MLST loci. The most common ST was ST1036, which com-
prised 11 isolates (23.91% of the data set), followed by ST1035,
which comprised 8 isolates (17.39%), and ST1039 with 5 isolates
(10.87%). The seven singleton STs (ST1370, ST1359, ST1358,
ST1211, ST1035, ST824, and ST52) included 17 isolates and ac-
counted for 36.95% of the data set. A total of seven clonal com-
plexes were identified (ST-21, ST-22, ST-42, ST-52, ST-257, ST-
353, and ST-354 complexes). Within each clonal complex, the
number of isolates ranged from 1 (ST-21, ST-42, and ST-257
complexes) to 12 (ST-353 complex). eBURST analysis allowed us
to determine the relationships between ST1040 (unassigned) and
ST1036 (ST-353 complex) on the one hand and ST1211 (ST-353
complex) on the other hand (Fig. 1). Indeed, the BURST analysis
revealed that both ST1040 and ST1036 belong to group 1,
whereas ST1211 was a singleton ST. ST1039 and ST1041 were
grouped in the same lineage (group 2) but were not assigned to
any complex based on the data in the Campylobacter MLST da-
tabase. The other STs that were not assigned to any complex were
ST1035 and ST1358. The IA for the complete data set was 2.028,
and the IA was 0.371 when only one representative of each lineage
was included.
Resistance phenotypes and mutations of the gyrA QRDR.
Twenty-four isolates were susceptible to both ciprofloxacin and
nalidixic acid, 3 isolates were susceptible to ciprofloxacin but
had intermediate susceptibility to nalidixic acid, and 19 isolates
were resistant to both antibiotics (Table 2). The great majority
of quinolone-resistant isolates had a change from C to T in
codon 86 of the gyrA gene, resulting in a threonine-to-isole-
ucine substitution in the functional protein. Another substitu-
tion in the same codon was the Thr-86-Ala substitution ob-
served in nalidixic acid-resistant isolates and isolates with
intermediate susceptibility. Forty-three isolates had silent mu-
tations at His-81 (CAC3CAT) and Ser-119 (AGT3AGC),
and 10 isolates had an additional silent mutation at Gly-110
(GGC3GGT).
Relationships between ST, resistance phenotypes, and gyrA
mutations. In all groups except group 3, the resistance pheno-
type varied within each ST (Table 2). However, certain phe-
notypes were predominant. In group 1, the most common
phenotype was double resistance to ciprofloxacin and nalidixic
acid, whereas groups 2 and 4 contained a majority of suscep-
tible isolates. In singleton STs, the resistance phenotypes were
diverse. Three phenotypes were identified among isolates as-
signed to ST1035, while ST52 contained only susceptible iso-
lates. Eleven of the 14 isolates having the Thr-86-Ile substitu-
tion belonged to group 1. Based on silent mutations, different
variants of the gyrA gene were shown to exist for the same ST
genotype; the first variant had a silent mutation at His-81 and
Ser-119, and the second variant had an additional silent mu-
tation at Gly-110.
DISCUSSION
The isolates analyzed in this study originated only from
chickens, in contrast to other studies in which isolates having
diverse origins were examined (8, 16). This study is the first
study in which the MLST approach was used to examine the
clonal relationships of C. jejuni isolates in Senegal. Although
the number of isolates was relatively small, the diversity of the
isolates was established by identification of various genotypes
and clonal complexes.
The allelic diversity observed here was similar to the diver-
sity observed previously in farm animals by Colles et al. (6)
with regard to the number of alleles and nucleotide variability;
the only exception was the uncA locus, for which Colles et al.
found a higher degree of diversity.
In this study, we identified seven clonal complexes, and all of
these complexes have been associated with human disease (9,
21). Consistent with our results, Dingle et al. (8) identified six
clonal complexes in 34 isolates obtained from chickens. In
contrast to previous studies in which the ST-21 complex was
the largest complex (6, 7, 8), this complex appears to be un-
common in Senegalese chickens since its ST1359 genotype
occurred only once in the data. The other complexes that were
less well represented were ST-42, ST-52, and ST-257. In Eu-
rope, these complexes were identified for various isolates from
TABLE 1. Allelic diversity
Locus Fragmentsize (bp)
No. of
alleles
No. of variables
sites
% Variable
sites dN/dS
a
aspA 477 5 6 1.3 0.022
glnA 477 9 13 2.7 0.006
gltA 402 6 6 1.5 0.062
glyA 507 6 22 4.3 0.001
pgm 498 8 24 4.8 0.000
tkt 459 7 17 3.7 0.002
uncA 489 4 3 0.6 0.043
a dN/dS, ratio of nonsynonymous substitutions to synonymous substitutions.
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farm animals (6, 16, 21) and also for human isolates (6, 21),
suggesting that they have a wide distribution. The ST-353 com-
plex, the most common complex in this study, and the ST-22
and ST-354 complexes have all been found previously in poul-
try (16). Other studies have shown that these complexes con-
tain isolates associated with human gastroenteritis (7, 9, 16).
Indeed, a search of the Campylobacter MLST database re-
vealed that these complexes contained a majority of the iso-
lates obtained from human disease. Despite the lack of MLST
data for humans in Senegal, one could envisage that these
complexes represent pathogen strains.
A number of new STs were identified for the first time in this
study (ST1035, ST1036, ST1037, ST1038, ST1039, ST1040,
ST1041, ST1081, ST1358, ST1359, and ST1370), and some of
them were not assigned to any known complex (ST1035,
ST1039, ST1040, ST1041, and ST1358). In group 1, for in-
stance, MLST showed that isolates with the ST1040 genotype
are single-locus variants of ST1036, which is a member of the
TABLE 2. MLST lineages, ST, gyrA mutations, and resistance phenotypes
BURST lineage Clonalcomplex ST Isolate Year gyrA mutations
a
Phenotypeb
Ciprofloxacin Nalidixicacid
Group 1 353 1036 83B 2001 His-81, Ser-119 S S
104C 2002 His-81, Ser-119 S S
116B 2002 His-81, Ser-119, Thr-86-Ile, Gly-110 R R
65B 2001 His-81, Ser-119, Thr-86-Ile R R
48A 2000 His-81, Ser-119, Thr-86-Ile R R
48B 2000 His-81, Ser-119, Thr-86-Ile R R
65A 2001 His-81, Ser-119, Thr-86-Ile R R
65C 2001 His-81, Ser-119, Thr-86-Ile R R
F19 2001 His-81, Ser-119, Thr-86-Ile R R
118C 2002 His-81, Ser-119, Thr-86-Ile, Gly-110 R R
82A 2001 His-81, Ser-119, Thr-86-Ile R R
Unassigned 1040 113B 2002 His-81, Ser-119, Thr-86-Ile R R
93A 2001 His-81, Ser-119 S S
112A 2002 His-81, Ser-119, Thr-86-Ile R R
Group 2 Unassigned 1039 50C 2000 His-81, Ser-119 S S
75A 2001 His-81, Ser-119 S S
95B 2001 His-81, Ser-119 S S
95A 2001 His-81, Ser-119 R R
57A 2001 His-81, Ser-119 S S
1041 62A 2001 His-81, Ser-119 S S
64C 2001 His-81, Ser-119 S S
F18 2001 His-81, Ser-119, Thr-86-Ala, Gly-110 R R
Group 3 22 1081 118B 2002 None S S
660 118A 2002 None S S
22 117C 2002 None S S
Group 4 354 1037 106B 2002 His-81, Ser-119, Thr-86-Ile R R
1038 113A 2002 His-81, Ser-119 S S
115B 2002 His-81, Ser-119 S S
V34A 2002 His-81, Ser-119 S S
Singleton STs 52 52 44B 2000 His-81, Ser-119 S S
47C 2000 His-81, Ser-119 S S
72B 2001 His-81, Ser-119 S S
55A 2001 His-81, Ser-119 S S
257 824 103C 2002 His-81, Ser-119 S S
21 1359 90B 2001 His-81, Ser-119 S S
353 1211 115A 2002 His-81, Ser-119 S S
42 1370 41B 2000 His-81, Ser-119 S S
Unassigned 1358 84C 2001 His-81, Ser-119 R R
1035 130A 2000 His-81, Ser-119, Gly-110 S S
76C 2001 His-81, Ser-119, Thr-86-Ala, Gly-110 S I
110B 2002 His-81, Ser-119, Thr-86-Ile, Gly-110 R R
76A 2001 His-81, Ser-119, Thr-86-Ala, Gly-110 S I
76B 2001 His-81, Ser-119, Thr-86-Ala, Gly-110 S I
78C 2001 His-81, Ser-119, Thr-86-Ala, Gly-110 R R
78A 2001 His-81, Ser-119, Thr-86-Ala, Gly-110 R R
110A 2002 His-81, Ser-119, Thr-86-Ile R R
a Silent mutations are His-81 (CAC3CAT), Ser-119 (AGT3AGC), and Gly-110 (GGC3GGT).
b R, resistant; S, susceptible; I, intermediate.
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ST-353 complex. eBURST analysis of all ST-353 complex iso-
lates in the MLST database with ST1040 indicated that ST1040
was derived from ST1036 (Fig. 1); the only difference was a
single nucleotide polymorphism in the gltA gene sequence.
Therefore, ST1040 probably diverged from ST1036 very re-
cently. Interestingly, based on eBURST and BURST analyses
of all ST-353 complex isolates in the MLST database it also
appeared that ST462 rather than ST353 was the founder of the
complex. As more MLST data are added to the database, more
new links should be seen, and it is also likely that conclusions
concerning the clonal complex founder will have to be modi-
fied. Also, eBURST analysis showed the relationship between
ST1211 and ST1036. ST1211 was grouped among the singleton
STs by BURST analysis, even though both ST1211 and ST1036
belonged to the ST-353 complex, and we explained this classi-
fication by the absence of intermediate STs (ST1232, ST462,
and ST353, not present among our isolates) between ST1211
and ST1036 and also by the fact that only three of the seven
MLST loci are shared by the two STs. Singleton STs were not
negligible in our study (36.95% of the data set), and they
represent distant genotypes not related to any other genotypes.
Thus, we believe that with more MLST data, new linkages (not
seen in this study) will be discovered. Another finding was that
group 2 contained only STs (ST1039 and ST1041) that were
not assigned to any complex. Perhaps these genotypes were the
result of recombination events (23). Based on the complete
data set, linkage analysis revealed that the IA was 2.028, which
is comparable to the value found by Dingle et al. (8) (2.016). In
our analysis, the IA was 0.371 when only one representative of
each lineage was included, whereas Dingle et al. (8) obtained
an IA of 0.56 and concluded that this indicated that there was
a weakly clonal population. In addition, Suerbaum et al. (23)
obtained an IA of 0.256, which was comparable to our value,
and suggested that there was a limited amount of recombina-
tion. Although the number of isolates analyzed in this study
was too small to draw any definite conclusions, certain STs
(ST1035, ST1036, and ST1039) and clonal complexes (ST-353,
ST-354, and ST-52 complexes) seem to be predominant, even
though other genotypes and clonal complexes may still be
present in Senegalese chickens.
As previously reported (1, 24), the Thr-86-Ile substitution in
the GyrA protein was the major mechanism of quinolone re-
sistance, although a small number of isolates had the Thr-86-
Ala substitution. In Senegal, fluoroquinolones (enrofloxacin
and norfloxacin) were introduced into poultry production in
1996 (4), and their use became an important selective factor in
the spread of quinolone-resistant clones. The fact that quino-
lone resistance was observed in STs of different MLST lineages
(except the ST-22 complex) suggests that the emergence of
quinolone resistance is not related to the diffusion of a unique
clone but rather is the result of quinolone selection pressure on
strains from different clones. Nevertheless, there might be a
relationship between isolates carrying the Thr-86-Ile substitu-
tion and the ST-353 complex. It also appeared that there were
different variants of the gyrA gene for the same ST genotype.
This illustrates the variability of the C. jejuni genome outside
the MLST loci. Previous studies have argued that gyrA poly-
morphism could be useful in epidemiological studies (13, 26).
We believe that this polymorphism may provide information
that supplements the data obtained by the MLST approach for
understanding the epidemiology of this pathogen. Generally
speaking, isolates that had the same ST genotype had variable
resistance phenotypes, suggesting that there was no link be-
tween ST genotype and quinolone resistance.
To date, there is little information concerning the epidemi-
ology of Campylobacter in Senegal, and in particular, there are
no data on human isolates due to the absence of systematic
investigations of Campylobacter in medical laboratories. This
report provides more insight into the molecular biology of this
bacterium in poultry production. Further studies with a larger
number of isolates, including isolates from humans and several
time frames, should provide more data on the epidemiology of
Campylobacter in Senegal.
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